1. Stiehm ER. Human gamma globulins as therapeutic agents. Adv Pediatr. 1988;35:1-72. doi: 10.1016/S0065-3101(24)00173-7, PMID 2461056
2. AQ4 EMEA Committee for Proprietary Medicinal Products (CPMP): Note for guidance on plasma derived medicinal products. CPMP/ BPWG/269/95. Ser. 2. London, 1998. Core. SPC for human anti-D immunoglobulin and human anti-D immunoglobulin for intravenous use, CPMP/BPWG/574/99, London, 1999. Core SPC for human normal immunoglobulin for intravenous administration (IVIg), CPMP/ BPWG/859/95 rev. Vol. 1, London, 1999. Core. SPC for human normal immunoglobulin for subcutaneous and intramuscular use (SC/IMIg) CPMP/BPWG/282/00, London; 2002.
3. AQ4 Pharmacopoea Europaea. Europaisches Arzneibuch. Amtliche Deutsche Ausgabe, DAV Stuttgart; 1997. p. 1289.
4. Gaines A, Varricchio F, Kapit R. Renal insufficiency and failure associated with immune globulin intravenous therapy-United States, 1985-1998. MMWR Morb Mortal Wkly Rep. 1999;48(24):518-21. PMID 10401909
5. Patil V, Kaveri SV. The mechanisms of action of IVIG in autoimmune and inflammatory diseases. ISBT Sci Ser. 2013;8(1):185-8. doi: 10.1111/voxs.12037